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96 Poster Session Ior alternative donors (mismatched-related, haplo-identical and
cord-blood, n 5 27) performed in a single institution since 1/
2001. GF was diagnosed in 25 patients (pts), cumulative incidence
(CI) 5.2% (95%ci 3.5–7.6). GF was determined when ANC had
not reached 0.5  10*9/L by day 21 (primary GF, n 5 21) or
when ANC decreased irreversibly after engraftment (secondary
GF, n 5 4). CI of GF was 2.5%, 6.8% and 23.4% after SCT
from siblings, MUD or alternative donors, respectively (p \
0.001) but was similar following myeloablative or reduced-intensity
conditioning (5.7% and 4.6%, respectively). Pts with a predominant
donor population in chimerism testing were given donor cell boost
with no additional conditioning (n 5 10). Pts with a predominant
host population were given autologous back-up cells (n5 8) or a sec-
ond SCT from a different donor (sibling-1, haplo-3, MUD-1) with
nonmyeloablative conditioning. 18 pts survived. 1 week after sec-
ond graft infusion and are evaluable for engraftment. 16 pts en-
grafted within a median of 10 days (range, 5–15). The probability
and pace of engraftment was similar in the different approaches.
11 pts (44%) were able to be discharged home and 14 died; 2 early
after diagnosis of GF with no intervention, 5 within one week of sec-
ond graft infusion and prior to engraftment, 2 with no engraftment
and 5 early after engraftment from infection (n5 3), organ failure (n
5 1) and GVHD (n 5 1). With a median follow-up of 19 months
(range, 3–68), 6 are alive and 5 additional pts died (relapse-3,
GVHD-1, infection-1). The projected 2-year survival for all pts
was 23% (95%ci 5–41). Interestingly, 4 pts given autologous cells
had donor cell recovery, 1 had spontaneous autologous reconstitu-
tion within 3 weeks, 2 died within 2 months (GVHD-1, infection-1)
with persistent donor cells and 1 remained complete donor until she
relapsed 2 years later. In conclusion, treatment of GF with a chime-
rism directed method can salvage a subset of pts with GF. Reserving
autologous and/or donor backup cells or an alternative donor is ad-
visable in pts at high-risk of GF. The observation of allogeneic re-
covery after autologous boost is intriguing and of unknown
mechanism.260
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We have previously demonstrated the safety and efficacy of RIAl-
loSCT in pediatric recipients (DelToro/Cairo et al, BMT, 2004;
Bradley/Cairo et al, BMT, 2007). RIAlloSCT in adults is associated
with a significant decrease in early bactermia (Junghanns et al,
BBMT, 2002), but not in incidence of IFI or CMV (Fukuda et al,
Blood 2003; Junghanns et al, Blood 2002). Date is lacking on inci-
dence and timing of SVI and IFI in children undergoing RIAl-
loSCT. We compared the incidence of SVI and IFI in children
receiving busulfan (BU)-based RIAlloSCT (group-A) vs. MA-Al-
loSCT (group-B) for various malignant and non-malignant dis-
eases. Regimens in group-A were BU (6.4–8 mg/kg)/Fludarabine
(FLU) (150–180 mg/m2) 6 ATG (n 5 36) and regimens in
group-B were BU (12.8–16 mg/kg)/FLU (150–180 mg/m2) 6
Alemtuzumab (n 5 17) vs. MA regimen (group-B) consisting of
BU (12.8–16 mg/kg)/Cyclophosphamide (120–200 mg/kg) or Mel-
phalan (135 mg/m2)6 ATG (n5 34). Median age: 7 yrs in group-A
(0.5–21) and 4.5 yrs in group B (0.3–21), respectively. Stem cell
source: UCB (group-A 5 31, group-B 5 20), PBSC (group-A 5
18, group-B5 6), BM (group-A5 4, group-B5 8). Donor source:
HLA-matched sibling (group-A 5 14, group-B 5 8), partially
matched related (group-A 5 3, group-B 5 2), unrelated (group-A
5 37, group-B 5 24). GVHD prophylaxis consisted of tacroli-
mus/MMF for most patients (Osunkwo/Cairo et al, BBMT,
2004). CMV at risk recipients received ganciclovir/foscarnet (Sher-
eck/Cairo et al, PBC, 2006) and most received antifungal prophy-laxis with liposomal amphotericin B until day -100 (Roman/Cairo
et al, PBC, 2007). Median follow-up: 782 days group-A/349 days
group-B. Median time to myeloid engraftment: 19 days group-A
& 20 days group-B. Incidence of aGVHD: 33% group-A/46%
group-B. Incidence of cGVHD: 31% group-A/25% group-B. SVI
were present in 27/53 pts (50%) in group-A and 22/34 pts (64%)
in group-B (p5ns); Table-1. IFI were present in 5/53 pts (9.4%)
in group-A, 5/34 pts (15%) in group-B (p5ns); Table-1. 3 pts
died 1 of RSV pneumonitis in group-A and 1 each of invasive asper-
gillus in group- A and B, respectively. Incidence of mortality sec-
ondary to SVI and IFI was 2/53 pts (3.7%) group-A, 1/34 pts
(2.9%) group-B. The estimated 1 yr OS was 77.7% (CI95: 65.7–
89.4) group-A and 63.8% (CI95: 57.4–80.3, p5ns) group-B. While
the incidence of SVI and IFI was similar in children undergoing RI
vs. MA-AlloSCT, further analysis is required to determine the im-
pact of RI conditioning on timing and mortality of SVI and IFI.
Group-A Group-B
Infection N 5 53 (%) N 5 34 (%)Adenovirus 5 (9.4) 2 (6)
CMV 5 (9.4) 5 (14)
EBV 0 0
RSV 10 (18) 6 (18)
Para-Influenza 4 (8) 5 (14)
Varicella 5 (9.4) 0
HSV 5 (9.4) 2 (6)
Influenza 2 (3.7) 2 (6)
BK-virus 7 (13) 9 (26)
Rota virus 4 (7.5) 2 (6)
Candida spp. 5 (9.4) 1 (3)
Asperigillus 3 (5.6) 0
Other fungii 1 (0.2) 1 (3)
Viral1fungal 14/31 (46)-UCB,
10/15 (62)-MRD, 4/7
(57)-MUD12/20 (60)-UCB,
8/10 (70)-MRD, 4/4
(100)-MUD261
THE PREVALENCE AND DETERMINANTS OF THE USE OF COMPLEMEN-
TARY AND ALTERNATIVE MEDICINE IN HEMATOPOIETIC STEM CELL
TRANSPLANTATION PATIENTS
Aksoy, S., Kocal, N., Akdogan, S., Ozdemir, E. Hacettepe University In-
stitute of Oncology, Ankara, Turkey.
Background: The aim of this study was to explore the use of
complementary and alternative medicine (CAM) in hematopoietic
stem cell transplantation (HSCT) patients. Methods: A descriptive
survey design was developed. Data was collected through a descrip-
tive questionnaire from 85 patients in outpatient HSCT clinic. Pa-
tients who underwent autologous or allogeneic stem cell
transplantation for hematological malignancies and were at least
100 days post-transplantation were included in this study. Results:
Seventy-two (55 male, 17 female) autologous and 13 (9 male, 4 fe-
male) allogeneic HSCT patients were included in the study. The
median age was 46 (range; 19–80) and median period of time
from the HSCT to evaluation was 24 months (range 4–86).
Thirty-six (42.4%) patients declared the use of some form of
CAM.
Median age of CAM using patients was 36 (range; 19–80) while
the others’ was 50 (range; 23–69) (p 5 0.14).
Patients treated with autologous HSCT reported more frequent
use of some form of CAM than the allogeneic ones (45.8% vs.
%23.1%) (p 5 0.10).
Females (66.7% vs. 34.9%) (p 5 0.01) and higher educated pa-
tients (52.9% vs. 26.5%) (p 5 0.013) used CAM more frequently
than the others. Married patients used CAM less frequently than
the others (35.9% vs. 61.9%) (p 5 0.01).
Herbal medicines and remedies were the most commonly used
CAM therapies. Urtica Dioica, Nigella Sativa and grape seed
were the most commonly used ones. The source of CAM-related in-
formation was mainly friends/family and the media. The majority
used CAM to increase the body’s ability to fight cancer or improve
